TABLE 3.
Effects of treatments with gel formulations containing 3% foscarnet, alone or in combination with 5% SLS, given twice daily for 3 days and initiated 24 h postinfection on the time evolution of HSV-1 titers in skin tissues and ipsilateral trigeminal ganglia
| Tissue | Treatment group | Virus titers (mean log PFU/g of tissue ± SD) on day:
|
% Virus positive | ||||
|---|---|---|---|---|---|---|---|
| 4 | 5 | 6 | 7 | 8 | |||
| Skin | Untreated | 6.19 ± 0.72 (3/3)a | 3.94 ± 0.71 (3/3) | 4.75 ± 0.66 (3/3) | 3.98 (1/3) | 0.00 (0/3) | 66.67 (10/15)a |
| Gel + 3% foscarnet | 5.75 ± 0.35 (3/3) | 5.75 ± 0.55 (3/3) | 4.50 ± 0.34 (3/3) | 3.49 (1/3) | 4.14 (1/3) | 73.33 (11/15) | |
| Gel + 3% foscarnet + 5% SLS | 3.85 ± 0.33 (2/3) | 5.63 ± 1.05 (3/3) | 6.35 (1/3) | 3.74 (1/3) | 2.31 (1/3) | 53.33 (8/15) | |
| Ganglia | Untreated | 7.05 ± 0.32 (3/3) | 5.20 ± 0.52 (3/3) | 4.74 ± 0.29 (3/3) | 3.46 (1/3) | 3.31 ± 0.29 (2/3) | 80.00 (12/15) |
| Gel + 3% foscarnet | 5.00 ± 2.67 (3/3) | 5.59 ± 0.44 (3/3) | 3.91 ± 0.23 (3/3) | 4.25 (1/3) | 4.23 (1/3) | 73.33 (11/15) | |
| Gel + 3% foscarnet + 5% SLS | 3.44 (1/3) | 5.49 ± 0.25 (3/3) | 5.74 (1/3) | 3.87 ± 0.40 (2/3) | 3.44 (1/3) | 53.33 (8/15) | |
a
The numbers of virus-positive tissues/numbers of samples tested are presented in parentheses.